Viatris | VTRS - Gross Profit On Sales

Stock Price
14.58
Daily Change
0.24 1.67%
Monthly
17.01%
Yearly
35.88%
Q1 Forecast
12.69

Viatris reported $1.37B in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Celltrion KRW 626.11B 81.75B Sep/2025
Cspc Pharmaceutical CNY 4.34B 333.68M Sep/2025
Dianthus Therapeutics USD 396K 203K Sep/2025
Divis Laboratories Ltd INR 14.54B 1.5B Jun/2025
Kangmei Pharma CNY 270.29M 20.26M Sep/2025
Knight Therapeutics CAD 44.83M 9.96M Jun/2025
Laboratorios Farma EUR 105.28M 177.08M Jun/2025
Medical Developments International AUD 7.35M 7.37M Jun/2025
Neuren Pharmaceuticals AUD 6.69M 6.37M Jun/2025
Organigram Holdings CAD 31.84M 23.88M Sep/2025
Pharma Mar EUR 33.36M 20.25M Sep/2025
Qiagen NV USD 344.8M 10.51M Sep/2025
Sartorius EUR 393.2M 23M Sep/2025
Sino Biopharmaceutical CNY 10.5B 2.53B Dec/2024
Tilray USD 67.63M 15.62M Mar/2025
Viatris USD 1.37B 38.6M Sep/2025
Zz Pientze Pharmaceu CNY 296.13M 1.1B Jun/2025